Employee Spotlight Our employee spotlight series celebrates the accomplishments and expertise of our valued scientists and staff. Hu Liu Hu Liu, PhD Director of Biologics Discovery Q&A with Dr. Liu What is your favorite part of your role here as Director of...
Employee Spotlight Our employee spotlight series celebrates the accomplishments and expertise of our valued scientists and staff. Amy (Zichun) Wang, PhD Amy (Zichun) Wang, PhD Senior Director of Cell Biology, Biology and Pharmacology Department Q&A with Amy What...
Employee Spotlight Our employee spotlight series celebrates the accomplishments and expertise of our valued scientists and staff. Yan Wang, PhD Yan Wang, PhD Director, Peptide Chemistry Q&A with Yan What is your favorite part of your role here as a Director of...
Employee Spotlight Our employee spotlight series celebrates the accomplishments and expertise of our valued scientists and staff. Manny Ventura, PhD Manny Ventura, PhD Senior Director and Site Head at ChemPartner US Q&A with Manny What is your favorite part of...
The race to first-in-human clinical trials has become more critical than ever for drug developers. The FDA has even developed 4 major tracks to speed up the process and make drugs available to patients as fast as possible: Fast Track: Facilitates drug development and...
Throughout the year, ChemPartner attends events and conferences around the world not only to stay up to date with the latest trends but to share our expertise with the industry. Mark your calendar with this year's top biopharma conferences and events, and be sure to...
Employee Spotlight Our employee spotlight series celebrates the accomplishments and expertise of our valued scientists and staff. Neha Yevalakar Neha Yevalekar Senior Scientist at ChemPartner Q&A with Neha What is your favorite part of your role here as a Senior...
The combined small and large molecule Contract Development and Manufacturing Organization (CDMO) market was valued at $52.8 billion dollars in 2021 with annual growth rates of 6.5% and 8.6% (respectively) from 2022 to 2030. So, why are more and more biotech and...
PD-L1 is a key inhibitor of T cell activation that is often over-expressed in cancer to escape immune surveillance and promote tumor progression. Blocking antibodies against PD-L1 or its receptor, PD-1, have shown significant clinical benefit in some patients with...